 | Up a level |
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, R D; Bernhard, J (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British journal of cancer, 106(10), pp. 1618-1625. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.156
Zaman, K; Thürlimann, B; Huober, J; Schönenberger, A; Pagani, O; Lüthi, J; Simcock, M; Giobbie-Hurder, A; Berthod, G; Genton, C; Brauchli, P; Aebi, S (2012). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of oncology, 23(6), pp. 1474-1481. Oxford University Press 10.1093/annonc/mdr448
Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J-M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology, 20(9), pp. 1489-98. Oxford: Oxford University Press 10.1093/annonc/mdp033
Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, J F; Aebi, S; Yeo, W; Thürlimann, B; Green, M D; Colleoni, M; Gelber, R D; Castiglione-Gertsch, M; Price, K N; Goldhirsch, A; Coates, A S (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer, 98(1), pp. 25-33. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604092
Gruber, G; Cole, B F; Castiglione-Gertsch, M; Holmberg, S B; Lindtner, J; Golouh, R; Collins, J; Crivellari, D; Thürlimann, B; Simoncini, E; Fey, M F; Gelber, R D; Coates, A S; Price, K N; Goldhirsch, A; Viale, G; Gusterson, B A (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of oncology, 19(8), pp. 1393-401. Oxford: Oxford University Press 10.1093/annonc/mdn123
Bernhard, J; Zahrieh, D; Castiglione-Gertsch, M; Hürny, C; Gelber, RD; Forbes, JF; Murray, E; Collins, J; Aebi, S; Thürlimann, B; Price, KN; Goldhirsch, A; Coates, AS; International, Breast Cancer Study Group Trial VIII (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Journal of clinical oncology, 25(3), pp. 263-70. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.04.5393
Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thürlimann, B; Mendiola, C; Aebi, S; Price, K N; Pagani, O; Simoncini, E; Castiglione Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology, 18(4), pp. 701-8. Oxford: Oxford University Press 10.1093/annonc/mdl492
Ribi, K; Bernhard, J; Rufibach, K; Thürlimann, B; von Moos, R; Ruhstaller, T; Glaus, A; Böhme, C (2007). Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. Supportive care in cancer, 15(12), pp. 1349-56. Berlin: Springer 10.1007/s00520-007-0258-3
Mauriac, L; Keshaviah, A; Debled, M; Mouridsen, H; Forbes, JF; Thürlimann, B; Paridaens, R; Monnier, A; Láng, I; Wardley, A; Nogaret, JM; Gelber, RD; Castiglione-Gertsch, M; Price, KN; Coates, AS; Smith, I; Viale, G; Rabaglio, M; Zabaznyi, N; Goldhirsch, A; ... (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of oncology, 18(5), pp. 859-67. Oxford: Oxford University Press 10.1093/annonc/mdm001
